Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Must- Read Articles
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Prevention Research
Cancer Prevention Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Must- Read Articles
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Review

New Perspectives of Curcumin in Cancer Prevention

Wungki Park, A.R.M. Ruhul Amin, Zhuo Georgia Chen and Dong M. Shin
Wungki Park
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A.R.M. Ruhul Amin
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhuo Georgia Chen
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dong M. Shin
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1940-6207.CAPR-12-0410 Published May 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

This article has a correction. Please see:

  • Correction: New Perspectives of Curcumin in Cancer Prevention - June 1, 2017

Abstract

Numerous natural compounds have been extensively investigated for their potential for cancer prevention over the decades. Curcumin, from Curcuma longa, is a highly promising natural compound that can be potentially used for chemoprevention of multiple cancers. Curcumin modulates multiple molecular pathways involved in the lengthy carcinogenesis process to exert its chemopreventive effects through several mechanisms: promoting apoptosis, inhibiting survival signals, scavenging reactive oxidative species (ROS), and reducing the inflammatory cancer microenvironment. Curcumin fulfills the characteristics for an ideal chemopreventive agent with its low toxicity, affordability, and easy accessibility. Nonetheless, the clinical application of curcumin is currently compromised by its poor bioavailability. Here, we review the potential of curcumin in cancer prevention, its molecular targets, and mechanisms of action. Finally, we suggest specific recommendations to improve its efficacy and bioavailability for clinical applications. Cancer Prev Res; 6(5); 387–400. ©2013 AACR.

Introduction

Cancer is a major health problem that can debilitate and destroy human lives. One out of every 4 deaths in the United States is caused by cancer. More than $124.6 billion was spent in direct medical costs for 13.7 million cancer survivors and 1.5 million newly diagnosed cancer patients in the United States in 2010. Increasing human life expectancy will inevitably raise cancer prevalence and the related costs. Consequently, the development of effective cancer prevention strategies is increasingly important. Histologically, the development of cancer involves multiple steps, which occur over several years after the initial carcinogen exposure from normal to hyperplasia, mild, moderate, and severe dysplasia, and carcinoma in situ, before finally progressing to invasive cancer (1). Throughout this long, multi-step developmental course, there is a wide scope of possible preventive approaches that can delay or prevent the development of cancer. Different cancer prevention strategies such as behavioral modification, vaccines, surgical manipulation, and chemoprevention have evolved with tremendous research efforts (2). Many investigations have proven that healthy lifestyles involving balanced diets, regular exercise, smoking cessation, alcohol reduction, weight control, and stress management are beneficial for decreasing cancer risk and can never be overemphasized (3–7). One particular milestone in cancer prevention was the approval by the U.S. Food and Drug Administration (FDA) of the human papilloma virus (HPV) cervical cancer vaccine in 2009 as a result of positive randomized controlled clinical trials.

The term chemoprevention was first coined in 1976 by M. B. Sporn, who defined it as a preventive modality in which natural or synthetic agents can be employed to slow, stop, reverse, or prevent the development of cancer. Since then, researchers have investigated numerous agents for this purpose with few successes. The first important translational study of a potentially chemopreventive agent was conducted with 13-cis retinoic acid (13-cRA), which resulted in successful size reduction of the premalignant lesion oral leukoplakia, albeit with some notable toxicities (8). In an attempt to reduce the toxicity, this study was followed by another trial using high-dose isotretinoin induction and maintenance with isotretinoin or beta-carotene, which suggested that isotretinoin is significantly more effective than beta-carotene against leukoplakia (9). Another follow-up study using low-dose isotretinoin and a large cohort of patients resulted in a negative outcome (10). In contrast, the field of breast cancer chemoprevention research gained considerable momentum after positive large-scale clinical trials of tamoxifen, a selective estrogen receptor modulator (SERM), led to its FDA approval (11). However, not all cancer types have successful chemoprevention stories. In colorectal cancer, despite positive secondary clinical trials of sulindac, celecoxib, and aspirin, primary prevention using cyclooxygenase-2 (COX-2) inhibitors was shown to have no benefit in the general population and the study was terminated early because of cardiovascular toxicity (12–14). Another disappointment was the recently conducted selenium and vitamin E cancer prevention trial (SELECT), which gave negative results in patients with lung and prostate cancers (15). After several large negative clinical trials were reported, the focus of the new era in chemoprevention has shifted toward molecularly targeted agents and less toxic natural compounds.

In chemoprevention, the safety of the participants is the first priority and should be considered of the utmost importance because essentially healthy people will receive the chemopreventive treatment for a long period of time. Moreover, the toxicity of the agents could impact patient accrual in larger scale studies in real clinical practice. To this end, unlike synthetic compounds, the safety of natural compounds present in fruits, vegetables, and spices are well established through their long-term consumption in human history (16). Therefore, taking natural compounds for cancer prevention can be a well-justified and effective strategy for people with increased risk for cancer development – such as those with premalignant lesions of intraepithelial neoplasia. Among many such natural compounds, curcumin has drawn special attention for its chemoprevention potential because of its safety, multi-targeted anticancer effects, and easy accessibility (16). The following sections will discuss different aspects of curcumin as a chemopreventive agent, including its safety, efficacy, and mechanism of action.

Curcumin in Chemoprevention

Since 1987, the National Cancer Institute (NCI) has tested more than 1,000 different potential agents for chemopreventive activity, of which only about 40 promising agents were moved to clinical trials (17). Curcumin, present in the Indian spice “haldi”, is 1 such agent that is currently under clinical investigation for cancer chemoprevention. Three polyphenols (Fig. 1) were isolated from Curcuma longa, of which curcumin (bis-α,β-unsaturated β-diketone) is the most abundant, potent and extensively investigated (16). Curcumin has been used empirically as a remedy for many illnesses in different cultures. It is only in the last few decades that curcumin's effects against cancer and cancer therapy-related complications have emerged, through much investigation. The first clinical report of the anticancer properties of curcumin was from Kuttan and coworkers, who used a 1% curcumin ointment on skin cancerous lesions with a reduction in smell in 90% of patients (18); 10% patients experienced a reduction in pain and lesion size. In an experimental model of mammary cancer induced by 7,12-dimethylbenz-[a]-anthracene (DMBA) in female rats, the initiation of DMBA-induced mammary adenocarcinoma was significantly decreased by intraperitoneal infusion of curcumin 4 days before DMBA administration (19). In a study of esophageal cancer prevention in curcumin-fed F344 rats, the chemopreventive activity of curcumin was observed not only in the initiation phase but also in post-initiation phases (20). In addition, in a familial adenomatous polyposis (FAP)-simulated study in which the APC gene of C57Bl/6J Min/+ mice was mutated to result in the development of numerous adenomas by 15 weeks of age, an oral curcumin diet prevented adenoma development in the intestinal tract, suggesting the chemopreventive effect of curcumin in colorectal cancer with APC mutation (21). Moreover, in a rat model of N-nitrosodiethylamine and phenobarbital-induced hepatic cancer, curcumin reduced lipid peroxidation and salvaged hepatic glutathione antioxidant defense, which eventually may have contributed to hepatic cancer prevention (22). Several studies of cancer prevention at different stages have shown the multi-targeted anticancer and chemopreventive effects of curcumin and have suggested it as a very favorable agent for chemoprevention.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Chemical structure of 3 polyphenols from Curcuma longa.

Mechanisms of Anticancer Effects

According to their mode of action, chemopreventive agents are classified into different subgroups: antiproliferatives, antioxidants, or carcinogen-blocking agents. Curcumin belongs to all 3 subgroups, given its multiple mechanisms of action. The anticancer effects of curcumin mainly result from multiple biochemical mechanisms that are involved in the regulation of programmed cell death and survival signals. The curcumin targets that are involved in signaling pathways include transcription factors, growth factors, inflammatory cytokines, receptors, and enzymes (Fig. 2). In different types of cancers, curcumin exhibits anticancer actions through a combination of different mechanisms, including survival signal reduction, proapoptotic promotion, anti-inflammatory actions, and reactive oxygen stress (ROS) scavenging to different degrees. The effects of curcumin on these signaling pathways are expected to be more complicated in the real setting, and the mechanisms of curcumin's chemopreventive, chemosensitizing, and radiosensitizing effects are more vigorously being studied now.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Molecular targets of curcumin. C, Curcumin; CIAP, cleavage inhibitor of apoptosis; FADD, Fas-associated protein with death domain; FLIP, FLICE-like inhibitory protein; DISC, death-inducing signaling complex; MOMP, mitochondrial outer membrane permeabilization; PKC, protein kinase C; PLC, phospholipase C; XIAP, X-linked inhibitor of apoptosis protein; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor; PDGF, platelet-derived growth factor; EGF, epidermal growth factor.

Survival signals – nuclear factor-κB

The survival signals in cancer cells are upregulated to support proliferation and survival against anticancer treatment. The central role players in this process are nuclear factor-κB (NF-κB), Akt, and their downstream cascades that can lead to the upregulation of antiapoptotic Bcl-2 proteins. Curcumin can modulate these signals by inhibiting the NF-κB pathways at multiple levels (23, 24). Curcumin significantly inhibited the growth of squamous cell carcinoma of head and neck (SCCHN) xenograft tumors in nude mice. Inhibition of nuclear and cytoplasmic IκB-β kinase (IKKβ) in the xenograft tumors decreased NF-κB activity (25). In addition, curcumin was shown to enhance chemosensitivity in 5-fluorouracil and cisplatin-treated esophageal adenocarcinoma as well as in paclitaxel-treated breast cancer cells by inhibiting compensatorily upregulated NF-κB (26). Likewise in a colon cancer cell line during radiotherapy, curcumin blocked NF-κB and reduced radioresistance (27).

Apoptotic signals—intrinsic and extrinsic

Curcumin induces programmed cell death (apoptosis) in many cancer cell types. Both intrinsic and extrinsic apoptotic pathways are activated by curcumin. In the intrinsic pathway, various cell stresses – irreversible DNA damage, defective cell cycle, or loss of growth factors – can generate death signals and ultimately pass them down to mitochondria. Then, depending on the balance of Bcl-2 family members, the destiny of the cell is driven into apoptosis. Curcumin upregulates the p53 modulator of apoptosis (PUMA) and Noxa, which, in turn, activates the proapoptotic multi-domain Bcl-2 family members Bax, Bim, and Bak and downregulates Bcl-2 and Bcl-xl. Loss of balance between pro- and antiapoptotic Bcl-2 proteins causes calcium influx into mitochondria and decrease in mitochondrial outer membrane permeability (MOMP) that allows cytochrome C and Smac release into the cytoplasm, eventually leading to the activation of a cascade of caspases and formation of the apoptosome, causing apoptosis (28).

In the extrinsic pathway, death signals are initiated from the exterior environment of the cells via Fas, tumor necrosis factor (TNF), and death receptors (DR) 3–6. When the signal is received, conformational change in the receptors allows Fas-associated death domain (FADD) binding and recruits the death-induced signaling complex (DISC), which activates the formation of initiator caspases 8 and 10. Curcumin was shown to upregulate extrinsic apoptosis pathway signals via the Fas pathway. In TNF-related-apoptosis-inducing ligand (TRAIL)-resistant cell lines, curcumin also enhanced apoptosis by upregulating the expression of DR 4 and 5 (29). After DISC recruitment, activation of the initiator caspases is regulated by FLICE-like inhibitory protein (FLIP) and curcumin was shown to downregulate c-FLIP in natural killer/T-cell lymphoma (30). Afterwards, the initiator caspase cleaves Bid and the truncated Bid (tBid) provides cross-talk between the intrinsic and extrinsic pathways by delivering death signals from initiator caspases directly to the mitochondrial pathway. In SKOV3 and OVCA429 ovarian carcinoma cells, curcumin showed induction of both intrinsic and extrinsic apoptosis by cleavage of pro-caspase 3, 8, 9, and cytochrome C release followed by tBid formation (31).

p53 plays a major role in tumor development and treatment; however, more than 50% of all cancers have p53 mutations. p53 proofreads DNA and recognizes uncorrectable mutations, at which point it arrests the cell cycle and steers the cell toward programmed cell death. Curcumin was shown to upregulate p53 expression followed by an increase in p21 (WAF-1/CIP-1), resulting in cell-cycle arrest at G0/G1 and/or G2/M phases. This is eventually followed by the upregulation of Bax expression, which induces apoptosis (32). On the other hand, curcumin has also shown its p53-independent anticancer effect as an inhibitor of the proteasome pathway by inhibiting ubiquitin isopeptidase (33). In a prostate cancer cell line, curcumin downregulated MDM2, the ubiquitous ligase of p53, and displayed enhanced anticancer effect via PI3K/mTOR/ETS2 pathways in PC3 xenografts in nude mice receiving gemcitabine and radiation therapy (34). In p53 mutant or knockout ovarian cancer cell lines, curcumin induced p53-independent apoptosis which involved p38 mitogen-activated protein kinase (MAPK) activation and inhibited Akt, resulting in decreased expression of Bcl-2 and survivin (31). Taken together, cancers with both deleted/mutant and wild-type p53 can benefit from curcumin treatment to achieve an anticancer effect.

Trophic signals—growth factors and cytokines

Different kinds of trophic factors including growth factors and cytokines can contribute to growth signals in cancer cells. Curcumin inhibits epidermal growth factor receptor (EGFR) kinase phosphorylation and strongly degrades Her2/neu protein, which ultimately inhibits cancer growth (35). In SCCHN, curcumin targets both EGFR and VEGF to inhibit cell growth (36). Therefore, the multi-targeted activity of curcumin may be potentially more effective. In an estrogen receptor-negative breast cancer cell line, curcumin inhibited angiogenesis factors such as VEGF and basic fibroblast growth factor (b-FGF) at the transcriptional level (37). Curcumin was also shown to inhibit expression of proinflammatory cytokines such as interleukin-1β (IL-1β) and IL-6 and exhibited growth inhibitory effects through inhibition of the NF-κB and MAPK pathways (38). In a breast cancer cell line, curcumin was shown to inhibit phosphorylation of Akt within the MAPK/PI3K pathway, which led to proapoptosis (39).

Roles of reactive oxidative stress

ROS has opposing effects on cancers: it can be an insult causing DNA mutations in carcinogenesis, and it can also drive mitochondrial apoptosis. Minimizing DNA insult by scavenging ROS is important for the prevention of cancer, while generating ROS to drive mitochondrial apoptosis is more important when treating malignancies. In terms of ROS scavenging, curcumin was shown to induce phase II metabolizing enzymes in male mice-glutathione-S-transferase (GST) and quinine reductase, which can neutralize ROS derived from chemical carcinogens (40). In addition, curcumin was shown to induce another important ROS scavenging enzyme – hemeoxygenase-1, the redox-sensitive inducible enzyme, via nuclear factor 2-related factor (Nrf-2) regulation (41). Curcumin is a ROS scavenging enzyme inducer but, on the other hand, it also uses ROS to kill cancer cells. ROS generated by curcumin in human renal Caki cell-downregulated Bcl-xl and inhibitors of apoptosis proteins (IAP), thereby inducing apoptosis (42). In cervical cancer cell lines, curcumin-generated ROS activated extracellular signal-regulated kinase (ERK), which modified radiosensitivity (43). Despite the paradoxical roles of curcumin in scavenging and generating ROS, the overall effect of curcumin is an anticancer activity.

Microenvironments—inflammation

Regarding the cancer microenvironment, the anticancer effect of curcumin is also described as being antagonistic to leaky vessels and loss of adhesion, which are closely related to cancer development and invasiveness. The relationship between the proinflammatory enzymes COX-2 and lipoxygenase (LOX) and the possible development of colorectal, lung, and breast cancers has been investigated (44). In colorectal cancer, development of the premalignant lesion aberrant crypt foci (ACF) was shown to be related to upregulated COX-2 level via inducible nitric oxide synthase (iNOS). As a nonspecific iNOS inhibitor, curcumin significantly inhibited colonic ACF formation in F344 rats (45). Moreover, curcumin downregulates CXCL-1 and -2 via NF-κB inhibition and, accordingly, downregulates the metastasis-promoting gene CXCR4 in a breast cancer cell line (46). In the normal Wnt pathway, β-catenin participates in the regulation of cell-to-cell adhesion integrity; however, in certain cancers, aberrant β-catenin accumulation promotes survival through an upregulated Akt pathway. In colon cancer cells, curcumin promoted caspase-3-mediated cleavage of β-catenin and decreased the level of the oncogene c-Myc (47). In addition, the invasiveness/metastasis of cancers was shown to be related to matrix metalloproteinase-9 (MMP-9) secretion, and treatment of an invasive hepatocellular cancer cell line with curcumin resulted in diminished invasiveness due to inhibition of MMP-9 secretion by curcumin (48).

Cancer stem cells and miRNA

Cancer stem cells (CSC) are a rare population of cells within the tumor having cell-renewal properties and are thought to be responsible for tumor initiation and treatment failures. The cancer stem-cell concept has important implications for cancer therapy and targeting CSCs is a relatively new strategy that can decrease cancer recurrence and relapse and treatment failure. Several studies have suggested that curcumin and its analogs can also target CSCs. In prostate cancer cells under hypoxic conditions, the curcumin analog CDF decreased CSC markers such as Nanog, Oct4, and EZH2 as well as miR-21, which contributed to deregulation of CSC function through the effects of CDF on the hypoxic pathway via HIF-1α (49). In colon cancer cells, STAT3 overexpression was found in ALDH(+)/CD133+ CSCs. The curcumin analog GO-Y030 inhibited the expression of STAT3 expression and suppressed CSC growth in colon cancer cells (50). Furthermore, in the rat glioma cell line C6, curcumin was shown to decrease the side population which is known to be associated with stem cell populations (51).

In addition, miRNAs play essential roles in tumorigenesis and anticancer drug development because of their ability to target both tumor suppressor and oncogenes. Curcumin and its analogs also target miR, which contributes to their chemopreventive potential. By controlling epigenetic gene expression via EZH2-miR regulation, CDF increased the levels of tumor-suppressive miR that are mostly absent in pancreatic cancer cells including let-7a, b, c, d, miR-26a, miR-101, miR-146a, and miR-200b, c and resulted in decreased pancreatic cancer cell survival and aggressiveness (49). Curcumin and its cyclohexanone and piperidine analogs inhibited growth of multiple colon cancer cells by targeting Sp transcription factors (52). Induction of the Sp repressors ZBTB10 and ZBTB4 and downregulation of miR-27a, miR-20a, and miR-17–5p by these compounds are important for inhibiting Sp transcription factors. In addition, miR-203, which regulates the Src–Akt axis, is a target of curcumin in bladder cancers (53).

Curcumin and host factors: Immunomodulation and metabolism

Because of poor bioavailability, it is practically impossible to reach the in vitro effective dose of curcumin in vivo. Nonetheless, curcumin is effective in vivo in inhibiting tumor growth and modulating biomarkers, suggesting that the host factors such as the host immune system and metabolic systems have an effect on its activities. Lack of functional T-cells or T-cell derived cytokines such as interferon-γ promotes spontaneous as well as carcinogen-induced tumorigenesis. CD8(+) cytotoxic T lymphocytes (CTL) are involved in antigen-specific tumor destruction and CD4(+) T cells are essential for helping this CD8(+) T–cell-dependent tumor eradication. Curcumin prevented loss of T cells, expanded T-cell populations, and reversed the type 2 immune bias and attenuated the tumor-induced inhibition of T-cell proliferation in tumor-bearing hosts (54). Moreover, curcumin inhibited the production of immunosuppressive cytokines such as TGF-B and IL-10 in these hosts. Another study suggested that increased CD8+ T cells enhance the production of INF-γ by curcumin (55). Another host effect is on the metabolism of curcumin, which involves 2 routes: 1 route transforms curcumin to hexahydrocurmin through successive reductions (probably through its intermediates dihydrocurcumin and tetrahydrocurcumin), while the other route involves rapid molecular modification by conjugation to glucuronide, sulfate, and glucuronide–sulfate forms (56). Although the main curcumin metabolites remain controversial, both in vivo and in vitro cell-free studies suggest that hydrocurcumins are more potent antioxidants than the parent curcumin in scavenging free radicals, reducing lipid peroxidation, and in enzyme activation (of superoxide dismutase, catalase, GSH peroxidase, and GST; refs. 57, 58). These antioxidant effects were shown to be critical for the chemopreventive potential of curcumin. Thus, curcumin displayed efficacy in vivo probably due to the presence of these host effects.

Clinical Trials of Curcumin Use in Cancer

Many positive preclinical cell line and animal model studies have brought curcumin to clinical trials to test its safety and efficacy as a chemopreventive agent. Several clinical trials have already been completed, the results of which are summarized in Table 1 (59–68). In phase I trials, curcumin was tested for its toxicity and tolerability, and was found to be highly tolerable at doses up to 12 g/d with no curcumin-related toxicities (60, 61). However, due to its poor bioavailability, curcumin was not detectable in blood when administered at doses up to 8 g, and was detected at very low levels following 10- and 12-g doses with a peak concentration at 1 to 2 hours. Histologic improvements of the lesions were observed in most of the treated patients (60). Radiologically stable disease was also shown in 5 out of 15 colorectal cancer patients who were refractory to chemotherapy in a second study (61). In a colorectal cancer trial, curcumin was shown to modulate biomarkers such as GST activity, deoxyguanosine adduct M(1)G, and PGE2 (prostaglandin E2; refs. 61–63). A decrease in lymphocytic GST activity of 59% resulted after administration of 440 mg of Curcuma extract (61). The levels of M(1) decreased from 4.8 ± 2.9 adducts per 107 nucleotides to 2.0 ± 1.8 adducts per 107 nucleotides after curcumin administration (63). Oral administration of 3.6 g curcumin significantly (P < 0.05) decreased inducible PEG2 production in blood 1 hour after curcumin administration as compared with the predosing level (62). The same study also showed the poor bioavailability and systemic distribution of curcumin. After encapsulated curcumin was administered in different amounts ranging from 0.45 to 3.6 g for 4 months, its biodistribution was examined by biopsy, which showed that malignant mucosal tissue had a higher concentration of curcumin while only a negligible amount was found in tissues outside the mucosa (61). This result may also be very beneficial for colorectal malignancy because any possible toxicity outside of the area of interest can be minimized. In 1 study where 5 FAP patients who had undergone a prior colectomy were treated with the combination of curcumin and quercetin for 6 months, the size and number of adenomas were reduced significantly, supporting the use of curcumin for FAP colorectal cancer prevention (66). Administration of 4 g curcumin per day for 30 days significantly inhibited (40%) the number of ACF although the 2 g/d dose was found to be ineffective (68). Several patients with advanced pancreatic cancers also responded to 8 g/d of curcumin treatment (69). These promising results are very convincing but need to be validated with further larger-scale randomized trials. Table 2 shows ongoing clinical studies with curcumin.

View this table:
  • View inline
  • View popup
Table 1.

Completed clinical trials using curcumin

View this table:
  • View inline
  • View popup
Table 2.

Ongoing clinical trials with curcumin

Biomarkers in Curcumin Chemoprevention Trials

Biomarkers can be very useful in identifying high-risk subjects for intervention, monitoring the effects of treatment, predicting outcome, and selecting patients who may benefit most from a given intervention. A well-validated biomarker may also serve as a surrogate endpoint to replace the current use of size reduction or histologic improvement of the precancerous lesion as the sole measure of success of chemoprevention; the use of a surrogate marker would potentially provide a more accurate assessment of outcome and would resolve the current difficulty in patient accrual due to the requirement for biopsy in chemoprevention clinical trials.

Although biomarkers for chemoprevention by curcumin have been extensively studied in cell culture and rodent models, only a few clinical studies have focused on biomarker modulation and attempted to correlate these with outcomes. In a recent pilot study, IKKβ kinase activity and the levels of proinflammatory cytokine IL-8 in the saliva of SCCHN patients were measured and the results suggested that IKKβ kinase activity could be used to detect the effect of curcumin treatment in SCCHN (70). In a double-blind randomized trial, curcumin was found to significantly decrease the levels of serum calcitonin gene-related peptide (CGRP) as compared with placebo (71). There were also significant decreases in serum IL-8 and high-sensitivity C-reactive protein (hs-CRP) in both the curcumin and placebo groups, with a higher magnitude in the curcumin group. In a placebo-controlled study, oral administration of curcumin significantly reduced erythrocyte malonaldehyde (MDA) and increased GSH levels in patients with tropical pancreatitis (72). Curcumin was also found to significantly decrease the serum levels of markers of oxidative damage (MDA and 8-hydroxydeoxyguanosine) and increase those of antioxidants (vitamins C and E) in patients with oral leukoplakia, oral submucous fibrosis, or lichen planus along with a significant decrease in pain and lesion size (73). Another clinical study suggested that cytokines and NF-kB pathway markers are important targets for curcumin chemoprevention (69). Other enzymes including COX-2 and hepatic GST nucleotidase have also been suggested for use in monitoring the effect of curcumin in chemoprevention studies (74). In addition, in a recent phase IIa clinical trial of curcumin chemoprevention in colorectal neoplasia, although the levels of PGE2 and 5-HETE did not significantly correlate with curcumin treatment, the amount of the premalignant lesion ACF was decreased (68); however, other studies showed marked modulation of PGE2 (62). To clarify these ambiguous results, many more clinical studies testing different surrogate biomarkers in larger patient numbers must be carried out to overcome the limitations to the study of surrogate monitoring biomarkers. On the basis of these previous results, however, biomarkers of oxidative stress, NF-kB pathway markers, and cytokine levels in serum and tissues appear to be promising markers that new studies should be designed to measure.

Hurdles: Pharmacokinetics and Pharmacodynamics

Phase I/II clinical trials have clearly shown that curcumin exhibits poor bioavailability in humans, reaching approximately 1% after oral administration, a major barrier for its use in the clinic. The major factors contributing to the low plasma and tissue levels of curcumin appear to be its poor absorption due to insolubility in water, rapid systemic elimination in the bile and urine due to extensive enterohepatic recirculation, and fast metabolism (56). In fact, 40% of orally administered curcumin is excreted unchanged in the feces. To circumvent the bioavailability problem, numerous approaches have been considered, including structural modification or modification of the delivery system such as adding adjuvant, liposomal curcumin, curcumin nanoparticles, and phospholipid complex.

Curcumin analogs

Studies suggest that the β-diketone moiety is responsible for the instability and weak pharmacokinetic profile of curcumin. Modifications of the structure of natural curcumin significantly improved solubility, stability, and bioavailability. James Snyder's group at the Emory University has synthesized a series of curcumin analogs by modifying the diketone moiety and the side chains of the benzene rings. Many of these compounds showed increased water-solubility and improved pharmacokinetic properties including tissue distribution and terminal elimination half-life (75). Analog HO3867 also showed tremendous improvement in cellular uptake and tissue distribution compared with its natural counterpart (76). Gagliardi and colleagues (77) synthesized more than 40 curcumin analogs and studied the bioavailability of some of these compounds in mice. One particular compound with a valine substitution at the phenyl ring showed more than 50-fold greater bioavailability compared with natural curcumin. A Japanese group also synthesized 86 different analogs of curcumin and determined their IC50 against 16 cancer cell lines. Many of these analogs, namely GO-Y078, 079, 030, 097, and 098, were at least 10-fold more potent than natural curcumin. This set of compounds is also more soluble in water, suggesting that they might show better bioavailability (78). Another synthetic curcumin known as dimethoxycurcumin exhibited significantly higher stability in vivo and against microsomal metabolism (79). In attempts to overcome the poor bioavailability of curcumin and to increase its tumor-specificity, many more innovative analogs have also been studied (Table 3; refs. 80–93).

View this table:
  • View inline
  • View popup
Table 3.

Curcumin analogs and their benefits

Curcumin nanoparticles

Delivery of drugs via their formulation as nanoparticles is an emerging platform for an efficient approach to improve pharmacokinetic properties such as solubility and stability and, thus, bioavailability of poorly bioavailable drugs. This approach has been extensively used for curcumin with success in preclinical studies. Formulation of curcumin by encapsulation in polymeric micelles, liposomes, polymeric nanoparticles, lipid-based nanoparticles, and hydrogels makes the formulation watersoluble (56). Many of these formulations also showed improved bioavailability and pharmacokinetic properties in vivo. Encapsulation of curcumin in polylactic-co-glycolic acid (PLGA) and PLGA–polyethylene glycol (PEG–PLGA-PEG) blend nanoparticles by a single-emulsion solvent-evaporation technique increased its mean half-life to approximately 4 and 6 hours, respectively, Cmax by 2.9- and 7.4-fold, and bioavailability by 15.6- and 55.4-fold, respectively (94). Encapsulation of curcumin in poly(butyl) cyanoacrylate (PBCA) nanoparticles led to a 52-fold increase in elimination half-life and 2-fold increase in AUC (95). Curcumin encapsulated in MePEO-b-PCL micelles also showed similar improvements in pharmacokinetic parameters (96). Formulation of curcumin in solid-lipid nanoparticles also tremendously increased its bioavailability (more than 80-fold higher concentration in blood; ref. 97).

Curcumin conjugates

Conjugation of curcumin with polymers or other lipophilic compounds is another widely used approach to improve the water-solubility and stability of curcumin. Conjugation of curcumin with hyaluronic acid or polyvinylpyrrolidone forms water-soluble micelles with improved stability at physiologic pH and cytotoxic activities (98, 99). Polymerization of curcumin using diacid also produced a water-soluble curcumin polymer with improved anticancer activity (100). Complexation of curcumin with phosphatidylcholine also significantly (3–20 fold) improved its pharmacokinetic parameters, including bioavailability in animal models (101).

Adding adjuvant

One of the major reasons for the poor bioavailability of curcumin is its rapid glucuronidation. Protection of curcumin from such metabolic conversion using an adjuvant was found to be successful in improving its bioavailability. Piperine is an inhibitor of intestinal and hepatic glucuronidation. Concomitant administration of curcumin with piperine increased the bioavailability of curcumin by 2000% in human volunteers and 154% in rats (59).

Future Possibilities

High-risk individuals and cancer survivors alike may benefit from chemoprevention, not only because primary cancer chemoprevention is beneficial for high-risk groups but also because of the devastating nature of the disease course when patients experience SPT or recurrence. As curcumin is a non-prescription dietary derivative that has multiple targets at different levels in multiple pathways, it has great potential in the prevention of cancer and SPT. When its systemic bioavailability is increased through the development of different analogs and formulations, the promise of curcumin in chemoprevention may be feasible in many cancer types, not necessarily limited only to gastrointestinal cancers. A number of new analogs and formulations have already been developed with higher systemic bioavailability and potency. More standardized clinical trials for bioavailability and randomized control trials for efficacy should validate the potential of these newer agents and formulations. First, specific trials can improve the application of curcumin through changing the route of administration, achieve targeted delivery straight to the lesion sites by increasing tumor-specific affinity, and develop different analogs that can bypass or minimize the first-pass metabolism occurring in the gastrointestinal mucosa and liver. Second, to minimize its metabolism before reaching the targeted site, different preparations of curcumin may improve its delivery to the target and, therefore, increase its bioavailability. Third, formulating curcumin using nanoparticles and microparticles, which are among the most innovative modalities that can maximize delivery to a target tissue and increase sensitivity and specificity, may enhance its therapeutic index.

Defining the optimal precancerous candidates and surrogate endpoints to properly assess chemopreventive response is mandatory in chemoprevention research. Although we expect the network of signaling pathways to be considerably more complicated than we currently understand, further studies will better dissect the molecular effects of curcumin in different cancers. Specifically, microarray or recently developed RNASeq studies may be particularly valuable in defining unknown positive and negative signaling loops, and may represent a new field of future research directed at understanding the critical factors necessary for chemoprevention. In the future, targeting specific patient populations with certain biomarkers, so-called tailored chemoprevention, is necessary. Defining critical biomarkers will help to better design a personalized plan for tailored chemoprevention. Progress in personal genome-based risk assessment and profiling of individual patients may also help to identify the patient population best suited to curcumin chemoprevention in the future.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: W. Park, A.R.M. Ruhul Amin, Z.G. Chen, D.M. Shin

Development of methodology: W. Park

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): W. Park

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): W. Park, A.R.M. Ruhul Amin

Writing, review, and/or revision of the manuscript: W. Park, A.R.M. Ruhul Amin, Z.G. Chen, D.M. Shin

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): D.M. Shin

Study supervision: Z.G. Chen

Grant Support

This work was supported, in whole or in part, by NIH Grants P50 CA128613 (D.M. Shin) and R03 CA159369 (A.R. Amin) as well as the Robbins Scholar Award (A.R. Amin).

Acknowledgments

The authors thank Anthea Hammond for editorial assistance. Wungki Park, A.R.M. Ruhul Amin, Zhuo Georgia Chen, and Dong M. Shin.

  • Received September 27, 2012.
  • Revision received January 31, 2013.
  • Accepted February 21, 2013.
  • ©2013 American Association for Cancer Research.

References

  1. 1.↵
    1. Haddad RI,
    2. Shin DM
    . Recent advances in head and neck cancer. N Engl J Med 2008;359:1143–54.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Lippman SM,
    2. Hawk ET
    . Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res 2009;69:5269–84.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Brennan JA,
    2. Boyle JO,
    3. Koch WM,
    4. Goodman SN,
    5. Hruban RH,
    6. Eby YJ,
    7. et al.
    Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:712–7.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Pollack ES,
    2. Nomura AM,
    3. Heilbrun LK,
    4. Stemmermann GN,
    5. Green SB
    . Prospective study of alcohol consumption and cancer. N Engl J Med 1984;310:617–21.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Thaker PH,
    2. Han LY,
    3. Kamat AA,
    4. Arevalo JM,
    5. Takahashi R,
    6. Lu C,
    7. et al.
    Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939–44.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Kenfield SA,
    2. Stampfer MJ,
    3. Giovannucci E,
    4. Chan JM
    . Physical activity and survival after prostate cancer diagnosis in the Health Professionals Follow-Up Study. J Clin Oncol 2011;29:726–32.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Calle EE,
    2. Rodriguez C,
    3. Walker-Thurmond K,
    4. Thun MJ
    . Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625–38.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Hong WK,
    2. Endicott J,
    3. Itri LM,
    4. Doos W,
    5. Batsakis JG,
    6. Bell R,
    7. et al.
    13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501–5.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Lippman SM,
    2. Batsakis JG,
    3. Toth BB,
    4. Weber RS,
    5. Lee JJ,
    6. Martin JW,
    7. et al.
    Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993;328:15–20.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Khuri FR,
    2. Lee JJ,
    3. Lippman SM,
    4. Kim ES,
    5. Cooper JS,
    6. Benner SE,
    7. et al.
    Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006;98:441–50.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Cuzick J,
    2. Forbes J,
    3. Edwards R,
    4. Baum M,
    5. Cawthorn S,
    6. Coates A,
    7. et al.
    First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817–24.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Giardiello FM,
    2. Hamilton SR,
    3. Krush AJ,
    4. Piantadosi S,
    5. Hylind LM,
    6. Celano P,
    7. et al.
    Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313–6.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Steinbach G,
    2. Lynch PM,
    3. Phillips RK,
    4. Wallace MH,
    5. Hawk E,
    6. Gordon GB,
    7. et al.
    The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–52.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Baron JA,
    2. Cole BF,
    3. Sandler RS,
    4. Haile RW,
    5. Ahnen D,
    6. Bresalier R,
    7. et al.
    A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891–9.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Lippman SM,
    2. Klein EA,
    3. Goodman PJ,
    4. Lucia MS,
    5. Thompson IM,
    6. Ford LG,
    7. et al.
    Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39–51.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Amin AR,
    2. Kucuk O,
    3. Khuri FR,
    4. Shin DM
    . Perspectives for cancer prevention with natural compounds. J Clin Oncol 2009;27:2712–25.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    http://prevention.cancer.gov/programs-resources/resources/agents. [accessed January, 2013].
  18. 18.↵
    1. Kuttan R,
    2. Sudheeran PC,
    3. Josph CD
    . Turmeric and curcumin as topical agents in cancer therapy. Tumori 1987;73:29–31.
    OpenUrlPubMed
  19. 19.↵
    1. Singletary K,
    2. MacDonald C,
    3. Wallig M,
    4. Fisher C
    . Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation by curcumin. Cancer Lett 1996;103:137–41.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Ushida J,
    2. Sugie S,
    3. Kawabata K,
    4. Pham QV,
    5. Tanaka T,
    6. Fujii K,
    7. et al.
    Chemopreventive effect of curcumin on N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats. Jpn J Cancer Res 2000;91:893–8.
    OpenUrlCrossRef
  21. 21.↵
    1. Perkins S,
    2. Verschoyle RD,
    3. Hill K,
    4. Parveen I,
    5. Threadgill MD,
    6. Sharma RA,
    7. et al.
    Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2002;11:535–40.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Sreepriya M,
    2. Bali G
    . Effects of administration of embelin and curcumin on lipid peroxidation, hepatic glutathione antioxidant defense and hematopoietic system during N-nitrosodiethylamine/phenobarbital-induced hepatocarcinogenesis in Wistar rats. Mol Cell Biochem 2006;284:49–55.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Shishodia S,
    2. Singh T,
    3. Chaturvedi MM
    . Modulation of transcription factors by curcumin. Adv Exp Med Biol 2007;595:127–48.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Notarbartolo M,
    2. Poma P,
    3. Perri D,
    4. Dusonchet L,
    5. Cervello M,
    6. D'Alessandro N
    . Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 2005;224:53–65.
    OpenUrlPubMed
  25. 25.↵
    1. Duarte VM,
    2. Han E,
    3. Veena MS,
    4. Salvado A,
    5. Suh JD,
    6. Liang LJ,
    7. et al.
    Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKbeta protein of the NFkappaB pathway. Mol Cancer Ther 2010;9:2665–75.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Hartojo W,
    2. Silvers AL,
    3. Thomas DG,
    4. Seder CW,
    5. Lin L,
    6. Rao H,
    7. et al.
    Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma. Transl Oncol 2010;3:99–108.
    OpenUrlPubMed
  27. 27.↵
    1. Sandur SK,
    2. Deorukhkar A,
    3. Pandey MK,
    4. Pabon AM,
    5. Sentu S,
    6. Guha S,
    7. et al.
    Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys 2009;75:534–42.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Shankar S,
    2. Srivastava RK
    . Involvement of Bcl-2 family members, phosphatidylinositol 3′-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol 2007;30:905–18.
    OpenUrlPubMed
  29. 29.↵
    1. Shankar S,
    2. Chen Q,
    3. Sarva K,
    4. Siddiqui I,
    5. Srivastava RK
    . Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis. J Mol Signal 2007;2:10.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Kim K,
    2. Ryu K,
    3. Ko Y,
    4. Park C
    . Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells. Br J Haematol 2005;131:59–66.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Watson JL,
    2. Greenshields A,
    3. Hill R,
    4. Hilchie A,
    5. Lee PW,
    6. Giacomantonio CA,
    7. et al.
    Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. Mol Carcinog 2010;49:13–24.
    OpenUrlPubMed
  32. 32.↵
    1. Choudhuri T,
    2. Pal S,
    3. Agwarwal ML,
    4. Das T,
    5. Sa G
    . Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett 2002;512:334–40.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Mullally JE,
    2. Fitzpatrick FA
    . Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death. Mol Pharmacol 2002;62:351–8.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Li M,
    2. Zhang Z,
    3. Hill DL,
    4. Wang H,
    5. Zhang R
    . Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 2007;67:1988–96.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Tikhomirov O,
    2. Carpenter G
    . Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res 2003;63:39–43.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Lin SS,
    2. Lai KC,
    3. Hsu SC,
    4. Yang JS,
    5. Kuo CL,
    6. Lin JP,
    7. et al.
    Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor (VEGF). Cancer Lett 2009;285:127–33.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Shao ZM,
    2. Shen ZZ,
    3. Liu CH,
    4. Sartippour MR,
    5. Go VL,
    6. Heber D,
    7. et al.
    Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer 2002;98:234–40.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Cho JW,
    2. Lee KS,
    3. Kim CW
    . Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med 2007;19:469–74.
    OpenUrlPubMed
  39. 39.↵
    1. Squires MS,
    2. Hudson EA,
    3. Howells L,
    4. Sale S,
    5. Houghton CE,
    6. Jones JL,
    7. et al.
    Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells. Biochem Pharmacol 2003;65:361–76.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Iqbal M,
    2. Sharma SD,
    3. Okazaki Y,
    4. Fujisawa M,
    5. Okada S
    . Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. Pharmacol Toxicol 2003;92:33–8.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Balogun E,
    2. Hoque M,
    3. Gong P,
    4. Killeen E,
    5. Green CJ,
    6. Foresty R,
    7. et al.
    Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 2003;371:887–95.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Woo JH,
    2. Kim YH,
    3. Choi YJ,
    4. Kim DG,
    5. Lee KS,
    6. Bae JH,
    7. et al.
    Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003;24:1199–208.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Javvadi P,
    2. Segan AT,
    3. Tuttle SW,
    4. Koumenis C
    . The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol Pharmacol 2008;73:1491–501.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Grosser T
    . The pharmacology of selective inhibition of COX-2. Thromb Haemost 2006;96:393–400.
    OpenUrlPubMed
  45. 45.↵
    1. Rao CV,
    2. Kawamori T,
    3. Hamid R,
    4. Reddy BS
    . Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis 1999;20:641–4.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Bachmeier BE,
    2. Mohrenz IV,
    3. Mirisola V,
    4. Schleicher E,
    5. Romeo F,
    6. Hohneke C,
    7. et al.
    Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. Carcinogenesis 2008;29:779–89.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Jaiswal AS,
    2. Marlow BP,
    3. Gupta N,
    4. Narayan S
    . Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 2002;21:8414–27.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Lin LI,
    2. Ke YF,
    3. Ko YC,
    4. Lin JK
    . Curcumin inhibits SK-Hep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion. Oncology 1998;55:349–53.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Bao B,
    2. Ahmad A,
    3. Kong D,
    4. Ali S,
    5. Azmi AS,
    6. Li Y,
    7. et al.
    Hypoxia-induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS ONE 2012;7:e43726.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Lin L,
    2. Liu Y,
    3. Li H,
    4. Li PK,
    5. Fuchs J,
    6. Shibata H,
    7. et al.
    Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. Br J Cancer 2011;105:212–20.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Fong D,
    2. Yeh A,
    3. Naftalovich R,
    4. Choi TH,
    5. Chan MM
    . Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals. Cancer Lett 2010;293:65–72.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Gandhy SU,
    2. Kim K,
    3. Larsen L,
    4. Rosengren RJ,
    5. Safe S
    . Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs. BMC Cancer 2012;12:564.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Saini S,
    2. Arora S,
    3. Majid S,
    4. Shahryari V,
    5. Chen Y,
    6. Deng G,
    7. et al.
    Curcumin modulates microRNA-203-mediated regulation of the Src–Akt axis in bladder cancer. Cancer Prev Res 2011;4:1698–709.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    1. Bhattacharyya S,
    2. Md Sakib Hossain D,
    3. Mohanty S,
    4. Sankar Sen G,
    5. Chattopadhyay S,
    6. Banerjee S,
    7. et al.
    Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts. Cell Mol Immunol 2010;7:306–15.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Luo F,
    2. Song X,
    3. Zhang Y,
    4. Chu Y
    . Low-dose curcumin leads to the inhibition of tumor growth via enhancing CTL-mediated antitumor immunity. Int Immunopharmacol 2011;11:1234–40.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Belkacemi A,
    2. Doggui S,
    3. Dao L,
    4. Ramassamy C
    . Challenges associated with curcumin therapy in Alzheimer disease. Expert Rev Mol Med 2011;13:e34.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Somparn P,
    2. Phisalaphong C,
    3. Nakornchai S,
    4. Unchern S,
    5. Morales NP
    . Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol Pharm Bull 2007;30:74–8.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Murugan P,
    2. Pari L
    . Antioxidant effect of tetrahydrocurcumin in streptozotocin-nicotinamide induced diabetic rats. Life Sci 2006;79:1720–8.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Shoba G,
    2. Joy D,
    3. Joseph T,
    4. Majeed M,
    5. Rajendran R,
    6. Srinivas PS
    . Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998;64:353–6.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Cheng AL,
    2. Hsu CH,
    3. Lin JK,
    4. Hsu MM,
    5. Ho YF,
    6. Shen TS,
    7. et al.
    Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895–900.
    OpenUrlPubMed
  61. 61.↵
    1. Sharma RA,
    2. McLelland HR,
    3. Hill KA,
    4. Ireson CR,
    5. Euden SA,
    6. Manson MM,
    7. et al.
    Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001;7:1894–900.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    1. Sharma RA,
    2. Euden SA,
    3. Platton SL,
    4. Cooke DN,
    5. Shafayat A,
    6. Hewitt HR,
    7. et al.
    Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10:6847–54.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Garcea G,
    2. Berry DP,
    3. Jones DJ,
    4. Singh R,
    5. Dennison AR,
    6. Farmer PB,
    7. et al.
    Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005;14:120–5.
    OpenUrlAbstract/FREE Full Text
  64. 64.↵
    1. Lao CD,
    2. Ruffin MT,
    3. Normolle D,
    4. Heath DD,
    5. Murray SI,
    6. Bailey JM,
    7. et al.
    Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006;6:10.
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. Bayet-Robert M,
    2. Kwiatkowski F,
    3. Leheurteur M,
    4. Gachon F,
    5. Planchat E,
    6. Abrial C,
    7. et al.
    Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 2010;9:8–14.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Cruz-Correa M,
    2. Shoskes DA,
    3. Sanchez P,
    4. Zhao R,
    5. Hylind LM,
    6. Wexner SD,
    7. et al.
    Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006;4:1035–8.
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Rafailov S,
    2. Cammack S,
    3. Stone BA,
    4. Katz AE
    . The role of Zyflamend, an herbal anti-inflammatory, as a potential chemopreventive agent against prostate cancer: a case report. Integr Cancer Ther 2007;6:74–6.
    OpenUrlAbstract/FREE Full Text
  68. 68.↵
    1. Carroll RE,
    2. Benya RV,
    3. Turgeon DK,
    4. Vareed S,
    5. Neuman M,
    6. Rodriguez L,
    7. et al.
    Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res 2011;4:354–64.
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    1. Dhillon N,
    2. Aggarwal BB,
    3. Newman RA,
    4. Wolff RA,
    5. Kunnumakkara AB,
    6. Abbruzzese JL,
    7. et al.
    Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008;14:4491–9.
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    1. Kim SG,
    2. Veena MS,
    3. Basak SK,
    4. Han E,
    5. Tajima T,
    6. Gjertson DW,
    7. et al.
    Curcumin treatment suppresses IKKbeta kinase activity of salivary cells of patients with head and neck cancer: a pilot study. Clin Cancer Res 2011;17:5953–61.
    OpenUrlAbstract/FREE Full Text
  71. 71.↵
    1. Panahi Y,
    2. Sahebkar A,
    3. Parvin S,
    4. Saadat A
    . A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 2012;49:580–8.
    OpenUrlCrossRefPubMed
  72. 72.↵
    1. Durgaprasad S,
    2. Pai CG,
    3. Vasanthkumar ,
    4. Alvres JF,
    5. Namitha S
    . A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 2005;122:315–8.
    OpenUrlPubMed
  73. 73.↵
    1. Rai B,
    2. Kaur J,
    3. Jacobs R,
    4. Singh J
    . Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci 2010;52:251–6.
    OpenUrlCrossRefPubMed
  74. 74.↵
    1. Shahani K,
    2. Panyam J
    . Highly loaded, sustained-release microparticles of curcumin for chemoprevention. J Pharm Sci 2011;100:2599–609.
    OpenUrlCrossRefPubMed
  75. 75.↵
    1. Zhu S,
    2. Moore TW,
    3. Lin X,
    4. Morii N,
    5. Mancini A,
    6. Howard RB,
    7. et al.
    Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts. Integr Biol (Camb) 2012;4:633–40.
    OpenUrlCrossRefPubMed
  76. 76.↵
    1. Dayton A,
    2. Selvendiran K,
    3. Kuppusamy ML,
    4. Rivera BK,
    5. Meduru S,
    6. Kalai T,
    7. et al.
    Cellular uptake, retention and bioabsorption of HO-3867, a fluorinated curcumin analog with potential antitumor properties. Cancer Biol Ther 2010;10:1027–32.
    OpenUrlCrossRefPubMed
  77. 77.↵
    1. Gagliardi S,
    2. Ghirmai S,
    3. Abel KJ,
    4. Lanier M,
    5. Gardai SJ,
    6. Lee C,
    7. et al.
    Evaluation in vitro of synthetic curcumins as agents promoting monocytic gene expression related to beta-amyloid clearance. Chem Res Toxicol 2012;25:101–12.
    OpenUrlCrossRefPubMed
  78. 78.↵
    1. Kudo C,
    2. Yamakoshi H,
    3. Sato A,
    4. Nanjo H,
    5. Ohori H,
    6. Ishioka C,
    7. et al.
    Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo . BMC Pharmacol 2011;11:4.
    OpenUrlPubMed
  79. 79.↵
    1. Tamvakopoulos C,
    2. Dimas K,
    3. Sofianos ZD,
    4. Hatziantoniou S,
    5. Han Z,
    6. Liu ZL,
    7. et al.
    Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res 2007;13:1269–77.
    OpenUrlAbstract/FREE Full Text
  80. 80.↵
    1. Tan X,
    2. Sidell N,
    3. Mancini A,
    4. Huang RP,
    5. Shenming W,
    6. Horowitz IR,
    7. et al.
    Multiple anticancer activities of EF24, a novel curcumin analog, on human ovarian carcinoma cells. Reprod Sci 2010;17:931–40.
    OpenUrlAbstract/FREE Full Text
  81. 81.↵
    1. Thomas SL,
    2. Zhao J,
    3. Li Z,
    4. Luo B,
    5. Du Y,
    6. Purcell J,
    7. et al.
    Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy. Biochem Pharmacol 2010;80:1309–16.
    OpenUrlCrossRefPubMed
  82. 82.↵
    1. Thomas SL,
    2. Zhong D,
    3. Zhou W,
    4. Malik S,
    5. Liotta D,
    6. Snyder JP,
    7. et al.
    EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle 2008;7:2409–17.
    OpenUrlPubMed
  83. 83.↵
    1. Kasinski AL,
    2. Du Y,
    3. Thomas SL,
    4. Zhao J,
    5. Sun SY,
    6. Khuri FR,
    7. et al.
    Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol 2008;74:654–61.
    OpenUrlAbstract/FREE Full Text
  84. 84.↵
    1. Olivera A,
    2. Moore TW,
    3. Hu F,
    4. Brown AP,
    5. Sun A,
    6. Liotta DC,
    7. et al.
    Inhibition of the NF-kappaB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. Int Immunopharmacol 2012;12:368–77.
    OpenUrlCrossRefPubMed
  85. 85.↵
    1. Devasena T,
    2. Menon VP,
    3. Rajasekharan KN
    . Prevention of 1,2-dimethylhydrazine-induced circulatory oxidative stress by bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione during colon carcinogenesis. Pharmacol Rep 2006;58:229–35.
    OpenUrlPubMed
  86. 86.↵
    1. Devasena T,
    2. Menon Venugopal VP,
    3. Rajasekaran KN
    . Chemoprevention of colon cancer by a synthetic curcumin analog involves amelioration of oxidative stress. Toxicol Mech Methods 2005;15:355–9.
    OpenUrlCrossRefPubMed
  87. 87.↵
    1. Kanwar SS,
    2. Yu Y,
    3. Nautiyal J,
    4. Patel BB,
    5. Padhye S,
    6. Sarkar FH,
    7. et al.
    Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res 2011;28:827–38.
    OpenUrlCrossRefPubMed
  88. 88.↵
    1. Padhye S,
    2. Banerjee S,
    3. Chavan D,
    4. Pandye S,
    5. Swamy KV,
    6. Ali S,
    7. et al.
    Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm Res 2009;26:2438–45.
    OpenUrlCrossRefPubMed
  89. 89.↵
    1. Fossey SL,
    2. Bear MD,
    3. Lin J,
    4. Li C,
    5. Schwartz EB,
    6. Li PK,
    7. et al.
    The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer 2011;11:112.
    OpenUrlCrossRefPubMed
  90. 90.↵
    1. Bill MA,
    2. Fuchs JR,
    3. Li C,
    4. Yui J,
    5. Bakan C,
    6. Benson DM Jr.,
    7. et al.
    The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer 2010;9:165.
    OpenUrlCrossRefPubMed
  91. 91.↵
    1. Sato A,
    2. Kudo C,
    3. Yamakoshi H,
    4. Uehara Y,
    5. Ohori H,
    6. Ishioka C,
    7. et al.
    Curcumin analog GO-Y030 is a novel inhibitor of IKKbeta that suppresses NF-kappaB signaling and induces apoptosis. Cancer Sci 2011;102:1045–51.
    OpenUrlCrossRefPubMed
  92. 92.↵
    1. Shibata H,
    2. Yamakoshi H,
    3. Sato A,
    4. Ohori H,
    5. Kakudo Y,
    6. Kudo C,
    7. et al.
    Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo . Cancer Sci 2009;100:956–60.
    OpenUrlCrossRefPubMed
  93. 93.↵
    1. Aggarwal S,
    2. Ndinguri MW,
    3. Solipuram R,
    4. Wakamatsu N,
    5. Hammer RP,
    6. Ingram D,
    7. et al.
    [DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo . Int J Cancer 2011;129:1611–23.
    OpenUrlCrossRefPubMed
  94. 94.↵
    1. Khalil NM,
    2. do Nascimento TC,
    3. Casa DM,
    4. Dalmolin LF,
    5. de Mattos AC,
    6. Hoss I,
    7. et al.
    Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces 2013;101:353–60.
    OpenUrlCrossRefPubMed
  95. 95.↵
    1. Duan J,
    2. Zhang Y,
    3. Han S,
    4. Chen Y,
    5. Li B,
    6. Liao M,
    7. et al.
    Synthesis and in vitro/in vivo anti-cancer evaluation of curcumin-loaded chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm 2010;400:211–20.
    OpenUrlCrossRefPubMed
  96. 96.↵
    1. Ma Z,
    2. Shayeganpour A,
    3. Brocks DR,
    4. Lavasanifar A,
    5. Samuel J
    . High-performance liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin. Biomed Chromatogr 2007;21:546–52.
    OpenUrlCrossRefPubMed
  97. 97.↵
    1. Wang W,
    2. Zhu R,
    3. Xie Q,
    4. Li A,
    5. Xiao Y,
    6. Li K,
    7. et al.
    Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine 2012;7:3667–77.
    OpenUrlPubMed
  98. 98.↵
    1. Manju S,
    2. Sreenivasan K
    . Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. J Colloid Interface Sci 2011;359:318–25.
    OpenUrlCrossRefPubMed
  99. 99.↵
    1. Manju S,
    2. Sreenivasan K
    . Synthesis and characterization of a cytotoxic cationic polyvinylpyrrolidone–curcumin conjugate. J Pharm Sci 2011;100:504–11.
    OpenUrlCrossRefPubMed
  100. 100.↵
    1. Tang H,
    2. Murphy CJ,
    3. Zhang B,
    4. Shen Y,
    5. Van Kirk EA,
    6. Murdoch WJ,
    7. et al.
    Curcumin polymers as anticancer conjugates. Biomaterials 2010;31:7139–49.
    OpenUrlCrossRefPubMed
  101. 101.↵
    1. Gupta NK,
    2. Dixit VK
    . Bioavailability enhancement of curcumin by complexation with phosphatidyl choline. J Pharm Sci 2011;100:1987–95.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Cancer Prevention Research: 6 (5)
May 2013
Volume 6, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Prevention Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
New Perspectives of Curcumin in Cancer Prevention
(Your Name) has forwarded a page to you from Cancer Prevention Research
(Your Name) thought you would be interested in this article in Cancer Prevention Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
New Perspectives of Curcumin in Cancer Prevention
Wungki Park, A.R.M. Ruhul Amin, Zhuo Georgia Chen and Dong M. Shin
Cancer Prev Res May 1 2013 (6) (5) 387-400; DOI: 10.1158/1940-6207.CAPR-12-0410

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
New Perspectives of Curcumin in Cancer Prevention
Wungki Park, A.R.M. Ruhul Amin, Zhuo Georgia Chen and Dong M. Shin
Cancer Prev Res May 1 2013 (6) (5) 387-400; DOI: 10.1158/1940-6207.CAPR-12-0410
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Curcumin in Chemoprevention
    • Mechanisms of Anticancer Effects
    • Clinical Trials of Curcumin Use in Cancer
    • Biomarkers in Curcumin Chemoprevention Trials
    • Hurdles: Pharmacokinetics and Pharmacodynamics
    • Future Possibilities
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Diet and DNA Damage Repair in Cancer
  • Cancer in Normal Weight Individuals with Metabolic Obesity
  • Cancer Chemoprevention with Mitochondria-targeted Agents
Show more Reviews
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Prevention Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Prevention Research
eISSN: 1940-6215
ISSN: 1940-6207

Advertisement